1477 — Ocumension Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- HK$6.98bn
- HK$6.57bn
- CNY804.35m
Annual cashflow statement for Ocumension Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -260 | -402 | -379 | -267 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 84.7 | 174 | 111 | 62 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -35.5 | -13.3 | 33.2 | -62.1 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -197 | -201 | -178 | -179 | — |
| Capital Expenditures | -665 | -310 | -362 | -230 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -680 | 539 | 102 | 506 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,345 | 229 | -260 | 276 | — |
| Financing Cash Flow Items | -10.7 | -1.79 | 119 | -2.25 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 669 | -9.22 | 109 | -214 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -909 | 44.8 | -327 | -114 | — |